Silicon Canals
No Result
View All Result
  • Home
  • News
    • News
    • Startups
    • Scaleups
    • Coin Canals
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Event News
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Exclusive content
    • Partner content
    • Community partners
    • Amsterdam
    • Rise by Techleap.nl
    • EOR handbook by Atlas HXM
    • Guest Contributions
    • Business Wire
    • Sign up for our newsletter!
  • Global Jobs
  • Tech Events
    • Technology Events
    • Event News
    • Submit event
  • Contact
    • Contact us
    • Contribute your content
    • Team
    • About us
  • Partner with us
  • Home
  • News
    • News
    • Startups
    • Scaleups
    • Coin Canals
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Event News
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Exclusive content
    • Partner content
    • Community partners
    • Amsterdam
    • Rise by Techleap.nl
    • EOR handbook by Atlas HXM
    • Guest Contributions
    • Business Wire
    • Sign up for our newsletter!
  • Global Jobs
  • Tech Events
    • Technology Events
    • Event News
    • Submit event
  • Contact
    • Contact us
    • Contribute your content
    • Team
    • About us
  • Partner with us
No Result
View All Result
Silicon Canals
No Result
View All Result

Dutch-Swiss medtech firm Xeltis lands €15M from EIB for its restorative approach in cardiovascular therapy

Editorial team by Editorial team
November 29, 2021
in (Crowd)funding, Health & Medtech, News, Startups
Xeltis

Image credits: Xeltis

39
SHARES
LinkedInTwitterWhatsAppFacebook
Read this article in:

Xeltis, a Swiss-Dutch medical device company, announced that it has secured €15M quasi-equity financing from the European Investment Bank (EIB). 

The financing is being made available under the European Guarantee Fund (EGF), a part of the €540B EU rescue package in response to the COVID-19 pandemic.

“In terms of medical technology innovations, what Xeltis is doing almost sounds like science fiction, yet it is already here,” says EIB Vice-President Kris Peeters. 

“I think Europe can be proud that it is a breeding ground for such cutting-edge technology, which has the potential to significantly impact medical care in a number of fields. I am proud that, with help of the European Guarantee Fund, we can get behind Xeltis to help them accelerate their way out of this difficult global phase,” he added. 

- Partner content -
Atlas HXM EOR Employee of Record
How EOR is becoming a crucial tool in 2023
EOR gains importance as companies digitise and hire globally. Learn from industry leaders...Show More
EOR gains importance as companies digitise and hire globally. Learn from industry leaders using EOR with Atlas HXM.Show Less
Read more

The fund will enable Xeltis to accelerate the clinical programmes of three restorative devices that can impact cardiovascular medicine. 

Eliane Schutte, CEO of Xeltis, says “EIB financial support can make the difference in the time our restorative heart valves and blood vessels reach patients that today have limited or no options at all for their conditions. Xeltis has the most advanced restorative technology platform in cardiovascular medicine and may positively impact millions of lives.”

Xeltis: What you need to know

Xeltis was formed through the merger of two Dutch/Swiss university spin-offs in 2006. The company has developed a polymer-based restorative device for cardiovascular treatment.

“The devices are made of supramolecular polymers shaped — through a process called electrospinning — into a microstructure that allows tissue restoration,” says the company.

The restorative devices comprise heart valves and small diameter blood vessels for coronary artery bypass graft (CABG) surgery and for hemodialysis vascular access. 

The company’s restorative heart valves enable the patient’s own body to naturally form a new heart valve through a therapeutic approach called Endogenous Tissue Restoration (ETR). 

With ETR, the patient’s natural healing system develops tissue that pervades Xeltis’ heart valve, forming a new, natural, and fully functional valve within it. 

As ETR occurs, Xeltis implants are gradually absorbed by the body.

Currently, the company has initiated the development of three types of cardiovascular implants: pulmonary heart valves, coronary artery bypass graft, and hemodialysis access grafts.

 - Partner content -
How to succesfully outsource…
How to succesfully outsource…
...your recruitment or product development with our curated community partners!
...your recruitment or product development with our curated community partners! Show Less
Read more
Tags: Dutch StartupsfundingHealth-& MedtechNetherlandsnewsstartups
Share3Tweet10SendShare16

Partner with us | Download Media Kit

Thank you for visiting Silicon Canals! If you want to partner with us, look at our options.

Featured | Tech Events

Current Month

september, 2023

Silicon Canals | Jobs

Breaking news from Amsterdam | Partner

Endeit Capital backs Amsterdam’s Lepaya in €35M round to revolutionise corporate learning through AI

Chemical Utopia: How Amsterdam Chemistry Network’s ChemAI aims to upend Dutch Chemistry

Amsterdam’s Truvity launches Truvity Platform to revolutionise digital identity verification technology

Partner content | Work with us

Amsterdam’s Invest-NL takes center stage in protecting Dutch companies from unwanted takeovers: Here’s how

[Exclusive] Amsterdam’s YourKitchen gets acquired by The Kitchen Dojo and Trias Real Estate: Know more

Meet Samaa Mohammad, an AI ethicist solving diversity problem with Techleap.nl’s DLiT Community

  • About Silicon Canals
  • Partner with Silicon Canals
  • Impressum
  • Contact us
  • Sign up for our newsletter!
  • Disclaimer
  • Privacy Policy
  • Cookie Policy (UK)
  • Cookie Policy (EU)
  • Terms & Conditions Silicon Canals

Silicon Canals © 2014-2023 | Design: Bright Idiots. Images: Depositphotos

No Result
View All Result
  • Home
  • News
    • News
    • Startups
    • Scaleups
    • Coin Canals
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Event News
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Exclusive content
    • Partner content
    • Community partners
    • Amsterdam
    • Rise by Techleap.nl
    • EOR handbook by Atlas HXM
    • Guest Contributions
    • Business Wire
    • Sign up for our newsletter!
  • Global Jobs
  • Tech Events
    • Technology Events
    • Event News
    • Submit event
  • Contact
    • Contact us
    • Contribute your content
    • Team
    • About us
  • Partner with us

Silicon Canals © 2014-2023 | Design: Bright Idiots. Images: Depositphotos

X
X